Clinical Trials in Mississauga, Ontario
28 recruiting
Showing 1–20 of 28 trials
Recruiting
Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Heart Failure
Boehringer Ingelheim4,200 enrolled641 locationsNCT06935370
Recruiting
Phase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Heart Failure
Boehringer Ingelheim6,000 enrolled652 locationsNCT06424288
Recruiting
Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S1,280 enrolled285 locationsNCT07207811
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1153 locationsNCT07064473
Recruiting
Phase 4
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Crohn's Disease
Takeda100 enrolled54 locationsNCT06045754
Recruiting
Phase 4
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
Ulcerative Colitis
Takeda65 enrolled49 locationsNCT06095128
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled217 locationsNCT06170788
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Crohn's Disease
Merck Sharp & Dohme LLC1,200 enrolled497 locationsNCT06430801
Recruiting
Phase 2
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
Heart Failure
Novo Nordisk A/S200 enrolled109 locationsNCT06979362
Recruiting
Phase 3
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Unresectable/Metastatic Melanoma
Canadian Cancer Trials Group614 enrolled30 locationsNCT02821013
Recruiting
Phase 2
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Endometrial Cancer
Canadian Cancer Trials Group393 enrolled100 locationsNCT05640999
Recruiting
Phase 3
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Major Depressive Disorder
Neumora Therapeutics, Inc.1,000 enrolled177 locationsNCT06029439
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled320 locationsNCT06136650
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled351 locationsNCT06065748
Recruiting
Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Colitis Ulcerative
Janssen Research & Development, LLC882 enrolled301 locationsNCT07196748
Recruiting
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
Crohn's Disease
Alimentiv Inc.300 enrolled25 locationsNCT06249555
Recruiting
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
Ulcerative Colitis (UC)Crohn Disease (CD)Inflammatory Bowel Disease (IBD)+1 more
TIDHI Innovation Inc.200 enrolled9 locationsNCT07245394
Recruiting
Phase 3
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca1,800 enrolled409 locationsNCT06120491
Recruiting
Phase 3
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Breast Cancer
Canadian Cancer Trials Group2,140 enrolled475 locationsNCT03488693
Recruiting
Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
Prostate Cancer
Canadian Cancer Trials Group710 enrolled53 locationsNCT06235697